BS_NRPG5K4K
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 58.04862023653088
- age_years
- 3.723
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.503
- INTERFERON_GAMMA_RESPONSE+0.494
- ALLOGRAFT_REJECTION+0.431
- CHOLESTEROL_HOMEOSTASIS+0.427
- INFLAMMATORY_RESPONSE+0.425
- TNFA_SIGNALING_VIA_NFKB+0.424
- IL6_JAK_STAT3_SIGNALING+0.417
- COAGULATION+0.411
- IL2_STAT5_SIGNALING+0.371
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.370
Top 10 suppressed
- E2F_TARGETS-0.538
- MYC_TARGETS_V2-0.478
- G2M_CHECKPOINT-0.470
- MYC_TARGETS_V1-0.417
- DNA_REPAIR-0.273
- SPERMATOGENESIS-0.191
- OXIDATIVE_PHOSPHORYLATION-0.157
- MITOTIC_SPINDLE-0.149
- PANCREAS_BETA_CELLS-0.132
- WNT_BETA_CATENIN_SIGNALING-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_V89HGTET | pilocytic astrocytoma | — | 0.979 |
| 2 | BS_M4TTKPNR | pilocytic astrocytoma | — | 0.962 |
| 3 | BS_HC5M8JTC | low-grade glioma | — | 0.953 |
| 4 | BS_GWCRMKE6 | pilocytic astrocytoma | — | 0.953 |
| 5 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.950 |
| 6 | BS_MF9X3PKH | low-grade glioma | — | 0.948 |
| 7 | BS_X16PENSA | pilocytic astrocytoma | — | 0.946 |
| 8 | BS_V3REENH9 | pilocytic astrocytoma | — | 0.945 |
| 9 | BS_014EVM2D | low-grade glioma | — | 0.944 |
| 10 | BS_GYXSDZ56 | pilocytic astrocytoma | — | 0.944 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.503 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.494 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.431 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.427 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.425 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.424 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.417 | Inavolisib | — uncovered |
| COAGULATION | 0.411 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.371 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.347 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.339 | Idelalisib | — uncovered |
| COMPLEMENT | 0.317 | Inavolisib | — uncovered |
| MYOGENESIS | 0.313 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.312 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.311 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.311 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.305 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.305 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.302 | Inavolisib | — uncovered |